Key Takeaways:
- The FDA's recent approval allows Amgen to expand Uplizna's reach, treating IgG4-related disease.
- Analysts estimate a potential rise in Amgen's stock price, indicating promising prospects.
- GuruFocus metrics suggest an upside potential of over 12% for Amgen Inc (AMGN, Financial).
Amgen Inc. (NASDAQ: AMGN) has achieved a significant milestone following the FDA's approval to broaden the application of Uplizna, specifically for treating adults with immunoglobulin G4-related disease (IgG4-RD). This decision is backed by compelling clinical trial results showing an impressive 87% reduction in the risk of disease flare-ups when compared to a placebo.
Wall Street Analysts Forecast
According to insights from 25 analysts, Amgen Inc. (AMGN, Financial) has an average one-year price target of $320.35. Projections vary, with a high of $389.00 and a low of $185.00, suggesting a potential upside of 3.39% from the current stock price of $309.85. For more comprehensive estimate data, visit the Amgen Inc (AMGN) Forecast page.
Delving into the consensus recommendation from 33 brokerage firms, Amgen Inc. (AMGN, Financial) currently holds an average brokerage recommendation of 2.5, reflecting an "Outperform" rating. This is based on a scale from 1 to 5, where 1 implies a Strong Buy and 5 indicates a Sell.
GuruFocus Valuation
GuruFocus estimates project the GF Value for Amgen Inc (AMGN, Financial) to rise to $347.42 in one year, revealing an upside potential of 12.13% from the present share price of $309.85. The GF Value represents GuruFocus' calculation of what the stock should ideally trade at, derived from historical trading multiples, past business growth, and anticipated future performance. Additional detailed information is available on the Amgen Inc (AMGN) Summary page.
